



The efficiency of the products using the Haemonetics bags has doubled. With the Acrodose™ Pooling Methodology we are able to now manufacture a platelet pool with 4.5 units of platelets. Compare that to just 20 years ago when we used to use 10 units of platelets. These efficiencies enable us to manufacture more therapeutic doses of platelets from the same number of platelet concentrates ... enabling us to do more with less."

Alicia Prichard
Senior Vice President, Biologics Department
OneBlood

Haemonetics helps OneBlood increase efficiency by 20%

Introduction

OneBlood is a not-for-profit community asset responsible for providing safe, available and affordable blood to more than 200 hospital partners and their patients throughout most of Florida and into parts of south Georgia and Alabama.

OneBlood was established on January 12, 2012 when three of Florida's independent, not-for-profit blood centers merged. Together, OneBlood brings more than 100 years of lifesaving experience to the community.

Integration

With the merger, came integration efforts and the need to bring the three blood centers into unified operational processes, policies and computer systems so they can function as one and create operational efficiencies.

Consistency was needed in streamlining the various platelet pooling processes in use across the organization to the Acrodose Methodology, which OneBlood determined was the most cost effective of all platelet pooling methods.

Innovation

OneBlood partnered with Haemonetics to drive efficiencies by:

1. Aligning and optimizing platelet collections with the implementation of Acrodose
2. Streamlining the flow of the platelet manufacturing processes
3. Calculating capacity requirements
4. Designing the functional requirements for a new, optimal "Platelet Room"

Results

As a result of the teamwork and collaboration between OneBlood and Haemonetics, OneBlood was able to:

- **Achieve increased platelet efficiency, with an average of 20% more platelets per pool.**

This was accomplished by helping OneBlood make a good, consistent platelet concentrate (PC) by optimizing their centrifuge profile.

- **Consistently achieve a targeted dose with as few as four units per pool.**

This was the result of an accuracy analysis performed by the Haemonetics team.

- **Reduce cost of the manufacturing process.**

This was accomplished by helping OneBlood streamline the Acrodose™ manufacturing pooling process, as well as the incorporation of other process flow improvements.



Because of the work the Haemonetics team has done to optimize our instruments and processes, I know that when I visit our manufacturing sites, the centrifuges are working optimally and making the best consistent platelet product for a patient in a hospital. I have no doubt about that," said Alicia Prichard, Senior Vice President of Biologics for OneBlood.

Future

OneBlood plans to continue building on the success of its partnership with Haemonetics as Alicia goes on to explain... "Working with the Haemonetics team has been a true partnership. They have helped us reduce costs and optimize our operations in all areas of our business. We look forward to continuing our successful work together to optimize production planning to drive down cost-per-unit collected for the entire OneBlood organization."

Acrodose Platelets

“ An Acrodose platelet offers a safe, efficient and readily-available option to platelet transfusion therapy with no safety or clinical sacrifice. With a five-day shelf life, Acrodose is an ABO matched, leukocyte-reduced, and bacterially contamination-screened product, which is more advantageous for patients.”

